Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
127 Results for "
CBP/P300
" in MedChemExpress (MCE) Product Catalog:
Products (127)
127 Results for "CBP/P300" in MCE Product Catalog:
Cat. No.: HY-W877997
CAS No.: 2467965-70-2
Research Areas:
Pomalidomide 5'-pip-acid is an E3 ligase ligand-linker conjugate derived from the molecular glue Pomalidomide (HY-10984), which can be used to synthesize the dual-target PROTAC degrader PROTAC CBP/p300/BRD4 Degrader-1 (HY-181758) targeting CBP/p300 and BRD4. Pomalidomide 5'-pip-acid shows anti-proliferative activity against cancer cells with an IC50 of 2.73 nM. Pomalidomide 5'-pip-acid induces anti-proliferative effects in cancer cells. Pomalidomide 5'-pip-acid is applicable to research related to prostate cancer and colorectal cancer .
Cat. No.: HY-19541A
CAS No.: 2147701-33-3
Research Areas:
I-CBP112 hydrochloride is a selective inhibitor of CBP/P300 that directly binds their bromodomains (Kds = 142 and 625 nM, respectively). I-CBP112 significantly reduces the leukemia-initiating potential of MLL-AF9(+) acute myeloid leukemia cells in a dose-dependent manner in vitro and in vivo. I-CBP112 increases the cytotoxic activity of BET bromodomain inhibitor JQ1 as well as doxorubicin .
Cat. No.: HY-161958
Target:
Research Areas:
dCE-2 is a CBP/EP300 PROTAC degrader with a DC50 of 40 nM against CBP. dCE-2 forms a ternary complex with the bromodomains of CBP/EP300 and the CRBN E3 ligase, driving proteasomal degradation of CBP/EP300 via positive cooperativity. dCE-2 is applicable to research related to multiple myeloma, prostate cancer, and neuroblastoma .
Cat. No.: HY-185786
CAS No.: 3105154-92-2
Research Areas:
CBP/p300-IN-25 is a CBP/p300 heterobifunctional conditional inhibitor. CBP/p300-IN-25 mediates conditional CBP/p300 inhibition through simultaneous binding to CBP/p300 and AR. CBP/p300-IN-25 is applicable to the research of prostate cancer .
Cat. No.: HY-111420R
CAS No.: 2443789-32-8
Research Areas:
CBP/p300-IN-1 (Standard) is the analytical standard of CBP/p300-IN-1 (HY-111420). This product is intended for research and analytical applications. CBP/p300-IN-1 is a CBP/EP300 bromodomain inhibitor.
Cat. No.: HY-175907
CAS No.: 2832963-93-4
Research Areas:
CBP/p300 ligand 7 is a p300/CBP ligand that can be used for the synthesis of PROTACs, such as QC-182 (HY-162259) .
Cat. No.: HY-181852
CAS No.: 3098454-51-1
Research Areas:
CBP/p300 ligand 10 (Compound 3-E) is a CBP/p300 degrader. CBP/p300 ligand 10 also serves as a PROTAC target protein ligand (Ligands for Target Protein for PROTACs) and can be used to synthesize the PROTAC CBP/p300 Degrader-2 (HY-181261) .
Cat. No.: HY-186064
CAS No.: 3102127-04-5
Research Areas:
CBP/p300 ligand-Linker Conjugate 3 is an Target Protein Ligand-Linker Conjugate that incorporates a ligand for CBP/p300 and a PROTAC linker, which recruits E3 ligases. CBP/p300 ligand-Linker Conjugate 3 can be used for synthesis of PROTAC CBP/P300 Degrader-2 (HY-181261) .
Cat. No.: HY-181261
CAS No.: 3102127-45-4
Target:
Research Areas:
PROTAC CBP/P300 Degrader-2 (compound 2) is a PROTAC-based CBP/P300 degrader that can be used in the research of cancer, autoimmune, inflammatory, and neurodegenerative diseases .
Target:
Research Areas:
(R,R)-CPI-1612 is the isomer of CPI-1612 (HY-136285), and can be used as an experimental control. CPI-1612 is a highly potent, orally active EP300/CBP histone acetyltransferase (HAT) inhibitor with an IC50 of 8.1 nM for EP300 HAT. CPI-1612 has an anticancer activity .
Target:
Research Areas:
(S,S)-CPI-1612 is the isomer of CPI-1612 (HY-136285), and can be used as an experimental control. CPI-1612 is a highly potent, orally active EP300/CBP histone acetyltransferase (HAT) inhibitor with an IC50 of 8.1 nM for EP300 HAT. CPI-1612 has an anticancer activity .
Cat. No.: HY-181759
CAS No.: 3086024-48-5
Research Areas:
CBP/p300/BRD4 ligand-1 is a small-molecule inhibitor targeting CBP, p300, and BRD4. CBP/p300/BRD4 ligand-1 competitively binds to the functional domains of target proteins without disrupting key interactions. CBP/p300/BRD4 ligand-1 can be used for the construction of dual-target PROTAC degraders (HY-181758) in studies related to prostate cancer and other cancers .
Cat. No.: HY-181758
CAS No.: 3109024-12-3
Research Areas:
PROTAC CBP/p300/BRD4 Degrader-1 is a dual-target PROTAC degrader with DC50 values of 8.8 pM (BRD4), 6.55 nM (CBP), and 1.05 nM (p300). PROTAC CBP/p300/BRD4 Degrader-1 induces CRBN- and proteasome-dependent degradation of BRD4 and CBP/p300, downregulates c-Myc and acetyl-H3K27, induces apoptosis. PROTAC CBP/p300/BRD4 Degrader-1 acts as an antiproliferative and antitumor agent, induces tumor growth inhibition in xenograft models. PROTAC CBP/p300/BRD4 Degrader-1 can be used for the research of prostate cancer and colorectal cancer .
Cat. No.: HY-187066
CAS No.: 2832964-54-0
Research Areas:
trans-CBP/p300 ligand 3-cyclohexane-CHO is a target protein ligand-linker conjugate. trans-CBP/p300 ligand 3-cyclohexane-CHO is used for the synthesis of PROTAC CBPD-268 (HY-161369) .
Cat. No.: HY-161498
Research Areas:
XYD198 (Compound 14h) is an orally active degrader for CBP/p300. XYD198 inhibits CBP/p300 bromodomain with IC50 of 213.5 nM. XYD198 exhibits antitumor activity against acute myeloid leukemia .
Cat. No.: HY-W173361
CAS No.: 56369-21-2
Research Areas:
CBP/p300-IN-24 is a selective CBP bromodomain inhibitor with an IC50 of 32 μM, showing selectivity over BRD4 BD-1 bromodomain. CBP/p300-IN-24 binds to the acetyl lysine binding pocket, forms hydrogen bonds with Asn1168 and a solvent-mediated hydrogen bond with Tyr1125, and forms hydrophobic interactions with Leu1120, Ile1122, and Val1174 .
Cat. No.: HY-123758
CAS No.: 2138461-99-9
Research Areas:
XDM-CBP is a CBP/p300 inhibitor. XDM-CBP can be used in the study of malignant melanoma, breast cancer and leukemia .
Cat. No.: HY-168464
Research Areas:
Y16526 is a potent inhibitor of CBP/p300 bromodomain , with the IC50 of 0.03 μM. Y16524 has the potential for the research of acute myeloid leukemia (AML) .
Cat. No.: HY-173641
CAS No.: 3067681-22-2
Research Areas:
MNN-02-155 is a bivalent molecular glue with with dual binding to p300/CBP and BCL6. MNN-02-155 induces potent activation of the BCL6-target reporter gene and cell death. MNN-02-155 can be used for the study of diffuse large B cell lymphomas (DLBCLs) .
Cat. No.: HY-160261S
CAS No.: 2379527-49-6
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
